Blockchain Registration Transaction Record

Optimi Health Advances Ibogaine Initiative with GMP-Grade Production Plans

Optimi Health announces progress on its Ibogaine Initiative, securing naturally derived ibogaine and planning GMP-grade production for research and therapeutic use.

This news matters because it signals a significant step forward in the development of ibogaine as a regulated therapeutic for mental health conditions like addiction and PTSD. With Optimi Health leveraging its existing GMP infrastructure and Canadian regulatory licenses, the company is poised to supply high-quality ibogaine for clinical research and potential therapeutic use. The growing public funding for psychedelic therapies, such as the $50 million program in Texas, indicates increasing acceptance and demand. For investors and patients, this development could accelerate access to ibogaine-based treatments and open new avenues in psychedelic medicine.